SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
14.9 EUR
-0.06 (-0.4%)
Taking everything into account, 1SXP scores 5 out of 10 in our fundamental rating. 1SXP was compared to 21 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
1SXP had positive earnings in 4 of the past 5 years.
Of the past 5 years 1SXP 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.61%, 1SXP belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
1SXP's Return On Equity of 17.02% is amongst the best of the industry. 1SXP outperforms 90.48% of its industry peers.
1SXP has a Return On Invested Capital of 13.92%. This is amongst the best in the industry. 1SXP outperforms 90.48% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is significantly above the industry average of 9.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROIC | 13.92% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
With an excellent Profit Margin value of 15.06%, 1SXP belongs to the best of the industry, outperforming 80.95% of the companies in the same industry.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
With an excellent Operating Margin value of 19.46%, 1SXP belongs to the best of the industry, outperforming 80.95% of the companies in the same industry.
1SXP's Operating Margin has improved in the last couple of years.
1SXP has a Gross Margin of 33.73%. This is in the lower half of the industry: 1SXP underperforms 66.67% of its industry peers.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1SXP is still creating some value.
1SXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 1.72, which is an excellent value as it means it would take 1SXP, only 1.72 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.72, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 90.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Altman-Z | N/A |
ROIC/WACC1.58
WACC8.81%
2.3 Liquidity
A Current Ratio of 1.57 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a Current ratio of 1.57. This is in the better half of the industry: 1SXP outperforms 71.43% of its industry peers.
A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a better Quick ratio (1.17) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -2.02% in the last year.
EPS 1Y (TTM)-2.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.44%
3.2 Future
The Earnings Per Share is expected to grow by 13.92% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.94% on average over the next years.
EPS Next Y18.66%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
EPS Next 5Y13.92%
Revenue Next Year8.43%
Revenue Next 2Y9.34%
Revenue Next 3Y9.27%
Revenue Next 5Y7.94%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 15.36, which indicates a correct valuation of 1SXP.
Based on the Price/Earnings ratio, 1SXP is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.59, 1SXP is valued a bit cheaper.
1SXP is valuated correctly with a Price/Forward Earnings ratio of 12.94.
Based on the Price/Forward Earnings ratio, 1SXP is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.
1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.36 | ||
| Fwd PE | 12.94 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 85.71% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1SXP is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.63 | ||
| EV/EBITDA | 8.58 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of 1SXP may justify a higher PE ratio.
1SXP's earnings are expected to grow with 15.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y16.45%
EPS Next 3Y15.84%
5. Dividend
5.1 Amount
1SXP has a Yearly Dividend Yield of 1.21%. Purely for dividend investing, there may be better candidates out there.
In the last 3 months the price of 1SXP has falen by -27.14%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 90.48% of the companies in the same industry.
Compared to the average S&P500 Dividend Yield of 1.88, 1SXP is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.40% of its income as dividend. This is a sustainable payout ratio.
DP16.4%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
FRA:1SXP (12/23/2025, 7:00:00 PM)
14.9
-0.06 (-0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.24B
Revenue(TTM)N/A
Net Income(TTM)146.90M
Analysts80
Price Target28.59 (91.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.4%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.61%
PT rev (3m)-4.36%
EPS NQ rev (1m)-4.49%
EPS NQ rev (3m)-4.49%
EPS NY rev (1m)-0.76%
EPS NY rev (3m)-2.08%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.36 | ||
| Fwd PE | 12.94 | ||
| P/S | 2.3 | ||
| P/FCF | 44.63 | ||
| P/OCF | 11.02 | ||
| P/B | 2.6 | ||
| P/tB | 2.69 | ||
| EV/EBITDA | 8.58 |
EPS(TTM)0.97
EY6.51%
EPS(NY)1.15
Fwd EY7.73%
FCF(TTM)0.33
FCFY2.24%
OCF(TTM)1.35
OCFY9.07%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)0.82
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROCE | 17.02% | ||
| ROIC | 13.92% | ||
| ROICexc | 14.45% | ||
| ROICexgc | 14.86% | ||
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% | ||
| FCFM | 5.15% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexgc growth 3Y-8.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 203.46% | ||
| Cap/Sales | 15.71% | ||
| Interest Coverage | 11.82 | ||
| Cash Conversion | 76.76% | ||
| Profit Quality | 34.23% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.81%
ROIC/WACC1.58
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y18.66%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
EPS Next 5Y13.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.44%
Revenue Next Year8.43%
Revenue Next 2Y9.34%
Revenue Next 3Y9.27%
Revenue Next 5Y7.94%
EBIT growth 1Y12.08%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year46.87%
EBIT Next 3Y21.99%
EBIT Next 5Y18.79%
FCF growth 1Y-27.75%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.4%
OCF growth 3Y19.45%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 5 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 15.36 and the Price/Book (PB) ratio is 2.6.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 4 / 10 and the dividend payout ratio is 16.4%.